These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29898975)

  • 1. Critical appraisal of the recent US FDA approval for earlier DBS intervention.
    Cabrera LY; Goudreau J; Sidiropoulos C
    Neurology; 2018 Jul; 91(3):133-136. PubMed ID: 29898975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on the Earlier Use of Deep Brain Stimulation for Parkinson Disease from a Qualitative Study of U.S. Clinicians.
    Cabrera LY; Sarva H; Sidiropoulos C
    World Neurosurg; 2019 Aug; 128():e16-e20. PubMed ID: 30880198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of FDA medical device regulation as it relates to deep brain stimulation devices.
    Peña C; Bowsher K; Costello A; De Luca R; Doll S; Li K; Schroeder M; Stevens T
    IEEE Trans Neural Syst Rehabil Eng; 2007 Sep; 15(3):421-4. PubMed ID: 17894274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA perspective on clinical trial design for cardiovascular devices.
    Chen E; Sapirstein W; Ahn C; Swain J; Zuckerman B
    Ann Thorac Surg; 2006 Sep; 82(3):773-5. PubMed ID: 16928481
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular device development: an FDA perspective.
    Zuckerman BD; Muni NI
    Am J Ther; 2005; 12(2):176-8. PubMed ID: 15767836
    [No Abstract]   [Full Text] [Related]  

  • 6. Prosthetic heart valves: Objective Performance Criteria versus randomized clinical trial.
    Grunkemeier GL; Jin R; Starr A
    Ann Thorac Surg; 2006 Sep; 82(3):776-80. PubMed ID: 16928482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Building comparative efficacy and tolerability into the FDA approval process.
    O'Connor AB
    JAMA; 2010 Mar; 303(10):979-80. PubMed ID: 20215612
    [No Abstract]   [Full Text] [Related]  

  • 8. Benefit-Risk Assessments at the US Food and Drug Administration: Finding the Balance.
    Califf RM
    JAMA; 2017 Feb; 317(7):693-694. PubMed ID: 28114599
    [No Abstract]   [Full Text] [Related]  

  • 9. The FDA approval process for medical devices: an inherently flawed system or a valuable pathway for innovation?
    Fargen KM; Frei D; Fiorella D; McDougall CG; Myers PM; Hirsch JA; Mocco J
    J Neurointerv Surg; 2013 Jul; 5(4):269-75. PubMed ID: 22764203
    [No Abstract]   [Full Text] [Related]  

  • 10. Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better.
    Mestre TA; Espay AJ; Marras C; Eckman MH; Pollak P; Lang AE
    Mov Disord; 2014 Dec; 29(14):1751-6. PubMed ID: 25227325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opening the FDA black box.
    Goodman SN; Redberg RF
    JAMA; 2014 Jan 22-29; 311(4):361-3. PubMed ID: 24449313
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence strength in FDA premarket approval of cardiovascular devices.
    Kong DF; Hasselblad V; Krucoff MW
    JAMA; 2010 Apr; 303(16):1599-600; author reply 1600-1. PubMed ID: 20424248
    [No Abstract]   [Full Text] [Related]  

  • 13. Myths and facts about the EARLYSTIM study.
    Schüpbach WM; Rau J; Houeto JL; Krack P; Schnitzler A; Schade-Brittinger C; Timmermann L; Deuschl G
    Mov Disord; 2014 Dec; 29(14):1742-50. PubMed ID: 25399678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of evidence behind FDA approvals varies widely.
    McCarthy M
    BMJ; 2014 Jan; 348():g1075. PubMed ID: 24470635
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulatory watch: Evaluating the potential for digital submission of expedited premarket safety reports to the FDA.
    Khozin S; Chuk M; Kim T; Kim G; Pazdur R; De S; Sahoo S
    Nat Rev Drug Discov; 2016 Sep; 15(10):670-1. PubMed ID: 27681787
    [No Abstract]   [Full Text] [Related]  

  • 17. [Early deep brain stimulation for Parkinson's disease].
    Schnitzler A; Fuchs G; Baas H; Dillmann U; Hilker R; Oechsner M
    Fortschr Neurol Psychiatr; 2010 Mar; 78 Suppl 1():S37-40. PubMed ID: 20195941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microarray data--the US FDA, industry and academia.
    Hackett JL; Lesko LJ
    Nat Biotechnol; 2003 Jul; 21(7):742-3. PubMed ID: 12833089
    [No Abstract]   [Full Text] [Related]  

  • 19. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study.
    Deuschl G; Schüpbach M; Knudsen K; Pinsker MO; Cornu P; Rau J; Agid Y; Schade-Brittinger C
    Parkinsonism Relat Disord; 2013 Jan; 19(1):56-61. PubMed ID: 22841616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New technology in electrophysiology: FDA process and perspective.
    Selzman KA; Fellman M; Farb A; de Del Castillo S; Zuckerman B
    J Interv Card Electrophysiol; 2016 Oct; 47(1):11-18. PubMed ID: 27020440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.